PATHFINDER

Mimicking pathogens; an integrated nano-medicine approach to developing intelligent cancer vaccines

Coordinatore	STICHTING KATHOLIEKE UNIVERSITEIT    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	2˙498˙680 €
EC contributo	2˙498˙680 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-AdG_20100317
Funding Scheme	ERC-AG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Wim Cognome: Van Oijen Email: send email Telefono: +31 24 3618937 Fax: +31 24 3540529	NL (NIJMEGEN)	hostInstitution	2˙498˙680.00
2	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Prof. Nome: Carl Gustav Cognome: Figdor Email: send email Telefono: +31 24 3617600 Fax: +31 24 3540339	NL (NIJMEGEN)	hostInstitution	2˙498˙680.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Tumour cells survive and grow because they are not effectively recognized by the immune system as ¿foreign¿ and are therefore not attacked and destroyed like most pathogens. We have already demonstrated the clinical value of dendritic cell (DC) vaccines that activate the immune system to fight cancer. Treating more than 300 patients with metastatic melanoma, we achieved extended survival in 40% of patients by maturing dendritic cells from the patient¿s blood in-vitro, loading them with cancer-specific antigens and re-injecting them into the patient. These DCs then activate tumour-specific T cells in the lymph nodes. Our success in this area of research makes us a world leader in dendritic cell immunotherapy. However, despite these encouraging results, more work needs to be done if this type of therapy is to move into routine cancer care.

Therefore the primary objective of the research detailed in this proposal is to significantly enhance cancer treatment efficacy by developing multifunctional nano-sized vaccine carriers that specifically target DCs and T cells in-vivo. If successful, this will also eliminate the costly in-vitro steps associated with current dendritic cell therapy.

The recent discovery of pathogen recognition receptors on dendritic cells opens up the possibility of exploiting these receptors to target dendritic cells within the body. We will therefore develop highly functionalized, slow-release vaccine carriers that target DCs in this way. In order to directly activate tumour-specific T cells, we will develop highly flexible polyisocyanide polymers that mimic naturally occurring DCs. To functionalize these polymers, we aim to develop a revolutionary DNA-based bar-coding technique. I expect this new approach leads to major advances in tumour immunotherapy.'